71.00
price up icon7.01%   4.65
after-market アフターアワーズ: 69.85 -1.15 -1.62%
loading
前日終値:
$66.35
開ける:
$63.33
24時間の取引高:
4.74M
Relative Volume:
4.77
時価総額:
$1.44B
収益:
$90.12M
当期純損益:
$-276.06M
株価収益率:
-48.63
EPS:
-1.46
ネットキャッシュフロー:
$-193.47M
1週間 パフォーマンス:
+102.16%
1か月 パフォーマンス:
+83.13%
6か月 パフォーマンス:
+200.85%
1年 パフォーマンス:
+9,613%
1日の値動き範囲:
Value
$62.00
$72.31
1週間の範囲:
Value
$34.47
$72.31
52週間の値動き範囲:
Value
$0.432
$72.31

Nektar Therapeutics Stock (NKTR) Company Profile

Name
名前
Nektar Therapeutics
Name
セクター
Healthcare (1112)
Name
電話
(415) 482-5300
Name
住所
455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA
Name
職員
61
Name
Twitter
@nektarnews
Name
次回の収益日
2025-03-12
Name
最新のSEC提出書
Name
NKTR's Discussions on Twitter

Compare NKTR vs VRTX, REGN, ARGX, ALNY, ONC

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
NKTR
Nektar Therapeutics
71.00 1.35B 90.12M -276.06M -193.47M -1.46
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
465.02 117.03B 11.74B 3.68B 3.34B 14.19
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
783.65 82.35B 14.34B 4.50B 3.77B 41.56
Biotechnology icon
ARGX
Argen X Se Adr
833.54 51.64B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
308.48 42.58B 3.21B 43.57M 221.36M 0.2405
Biotechnology icon
ONC
Beone Medicines Ltd Adr
346.42 38.87B 4.98B 69.60M 525.67M 0.5198

Nektar Therapeutics Stock (NKTR) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-11-26 開始されました Citigroup Buy
2025-06-24 繰り返されました BTIG Research Buy
2025-06-24 繰り返されました H.C. Wainwright Buy
2025-04-11 アップグレード Jefferies Hold → Buy
2025-03-14 アップグレード Oppenheimer Perform → Outperform
2025-01-08 開始されました B. Riley Securities Buy
2024-12-10 開始されました H.C. Wainwright Buy
2024-11-04 開始されました Piper Sandler Overweight
2024-09-30 再開されました BTIG Research Buy
2024-06-28 開始されました Rodman & Renshaw Buy
2023-11-20 再開されました JP Morgan Underweight
2023-11-09 アップグレード TD Cowen Market Perform → Outperform
2023-05-10 アップグレード Jefferies Underperform → Hold
2023-02-24 ダウングレード Jefferies Hold → Underperform
2022-08-08 ダウングレード JP Morgan Neutral → Underweight
2022-05-31 再開されました Jefferies Hold
2022-04-18 ダウングレード Goldman Neutral → Sell
2022-03-15 ダウングレード Cowen Outperform → Market Perform
2022-03-15 ダウングレード Mizuho Buy → Neutral
2022-03-14 ダウングレード BTIG Research Buy → Neutral
2022-03-14 ダウングレード BofA Securities Neutral → Underperform
2022-03-14 ダウングレード Stifel Buy → Hold
2022-03-14 ダウングレード William Blair Outperform → Mkt Perform
2022-03-09 アップグレード Oppenheimer Perform → Outperform
2021-11-08 アップグレード The Benchmark Company Hold → Buy
2021-09-10 開始されました BofA Securities Neutral
2021-06-28 アップグレード Stifel Hold → Buy
2021-05-18 再開されました Goldman Neutral
2021-02-22 ダウングレード The Benchmark Company Buy → Hold
2021-01-06 開始されました Stifel Hold
2020-09-14 開始されました JP Morgan Neutral
2020-06-10 ダウングレード CFRA Hold → Sell
2020-05-12 繰り返されました H.C. Wainwright Neutral
2020-04-22 開始されました The Benchmark Company Buy
2020-03-30 アップグレード Goldman Sell → Neutral
2020-03-04 開始されました Barclays Overweight
2020-02-03 アップグレード Mizuho Neutral → Buy
2019-10-24 開始されました Oppenheimer Perform
2019-10-08 ダウングレード Goldman Buy → Sell
2019-08-09 ダウングレード JP Morgan Overweight → Neutral
2019-08-09 ダウングレード Jefferies Buy → Hold
2019-08-09 ダウングレード Mizuho Buy → Neutral
2019-03-15 開始されました SVB Leerink Mkt Perform
2018-12-13 開始されました Goldman Buy
2018-06-11 ダウングレード H.C. Wainwright Buy → Neutral
2018-06-04 繰り返されました H.C. Wainwright Buy
2018-04-20 開始されました Seaport Global Securities Buy
2018-04-13 再開されました Piper Jaffray Overweight
2018-04-06 繰り返されました Mizuho Buy
2018-04-02 再開されました H.C. Wainwright Buy
すべてを表示

Nektar Therapeutics (NKTR) 最新ニュース

pulisher
12:48 PM

Nektar CEO looks to add $400 milllion for atopic dermatitis drug - The Business Journals

12:48 PM
pulisher
09:20 AM

Nektar Therapeutics stock falls after $400 million public offering By Investing.com - Investing.com UK

09:20 AM
pulisher
08:51 AM

Nektar Therapeutics (NKTR) Is Up 88.9% After Upsized Equity Raise And Positive REZOLVE-AD DataHas The Bull Case Changed? - simplywall.st

08:51 AM
pulisher
08:44 AM

Nektar Therapeutics (NASDAQ:NKTR) Sets New 12-Month HighHere's Why - MarketBeat

08:44 AM
pulisher
08:16 AM

Nektar Therapeutics' (NASDAQ:NKTR) Shares Climb 81% But Its Business Is Yet to Catch Up - simplywall.st

08:16 AM
pulisher
07:48 AM

HC Wainwright Expects Lower Earnings for Nektar Therapeutics - MarketBeat

07:48 AM
pulisher
05:12 AM

Nektar Therapeutics Prices $400 Million Offering of Stock, Pre-Funded Warrants - marketscreener.com

05:12 AM
pulisher
04:22 AM

Nektar Therapeutics prices $400M stock offering - MSN

04:22 AM
pulisher
01:07 AM

Nektar Therapeutics (NKTR) Finalizes $400M Stock Offering - GuruFocus

01:07 AM
pulisher
Feb 11, 2026

Nektar Therapeutics announces pricing of upsized $400 million public offering - marketscreener.com

Feb 11, 2026
pulisher
Feb 11, 2026

Nektar Therapeutics Announces Pricing Of Upsized $400 Million Public Offering - TradingView

Feb 11, 2026
pulisher
Feb 11, 2026

Nektar Therapeutics Announces Pricing of Upsized $400 Million Public Offering - PR Newswire

Feb 11, 2026
pulisher
Feb 11, 2026

Nektar Therapeutics stock hits 52-week high at 66.97 USD By Investing.com - Investing.com Nigeria

Feb 11, 2026
pulisher
Feb 11, 2026

Nektar Therapeutics Announces Proposed Public Offering - The Malaysian Reserve

Feb 11, 2026
pulisher
Feb 11, 2026

Rezpegaldesleukin maintenance data show durable responses in moderate-to-severe atopic dermatitis - Contemporary Pediatrics

Feb 11, 2026
pulisher
Feb 11, 2026

Nektar Therapeutics stock pops on $300M equity offering - MSN

Feb 11, 2026
pulisher
Feb 11, 2026

Nektar Stock Soars Amid Promising Developments and Analyst Upgrades - StocksToTrade

Feb 11, 2026
pulisher
Feb 11, 2026

Nektar seeks US$300m for promising eczema drug - ifr-logo

Feb 11, 2026
pulisher
Feb 11, 2026

Nektar Therapeutics stock hits 52-week high at 66.97 USD - Investing.com

Feb 11, 2026
pulisher
Feb 11, 2026

Nektar Stock Surges On Rezpegaldesleukin Phase 2b Maintenance Data: What It Means - Seeking Alpha

Feb 11, 2026
pulisher
Feb 11, 2026

Nektar’s Rezpegaldesleukin Shows Promise, Analysts Raise Price Targets - timothysykes.com

Feb 11, 2026
pulisher
Feb 11, 2026

Nektar Therapeutics (NASDAQ:NKTR) Sees Unusually-High Trading Volume on Analyst Upgrade - MarketBeat

Feb 11, 2026
pulisher
Feb 11, 2026

BTIG Lifts Nektar Price Target Amidst Promising Atopic Dermatitis Treatment - StocksToTrade

Feb 11, 2026
pulisher
Feb 11, 2026

Nektar Therapeutics (NKTR) Shares Surge on $300M Public Offering Announcement - GuruFocus

Feb 11, 2026
pulisher
Feb 11, 2026

Nektar’s Rezpeg Differentiates in Atopic Dermatitis With Durable, Deep Responses in Mid-Stage - BioSpace

Feb 11, 2026
pulisher
Feb 11, 2026

A Quick Look at Today's Ratings for Nektar Therapeutics(NKTR.US), With a Forecast Between $102 to $165 - 富途牛牛

Feb 11, 2026
pulisher
Feb 11, 2026

Nektar Shares Surge On Phase IIb Rezpeg Atopic Dermatitis Data - Citeline News & Insights

Feb 11, 2026
pulisher
Feb 11, 2026

Nektar’s stock rises 51% on Phase II Rezpeg AD maintenance win - Yahoo Finance

Feb 11, 2026
pulisher
Feb 11, 2026

Q3 EPS Forecast for Nektar Therapeutics Boosted by Analyst - MarketBeat

Feb 11, 2026
pulisher
Feb 11, 2026

Why Is Nektar Therapeutics Stock Gaining Wednesday? - Benzinga

Feb 11, 2026
pulisher
Feb 11, 2026

Biopharma companies Evommune and Nektar soar on eczema treatment data - Mugglehead Investment Magazine

Feb 11, 2026
pulisher
Feb 11, 2026

Nektar Therapeutics (NKTR) stock jumps again premarket after 51% surge; $300 million offering in focus - Bez Kabli

Feb 11, 2026
pulisher
Feb 11, 2026

Nektar reports positive long-term data for atopic dermatitis drug By Investing.com - Investing.com South Africa

Feb 11, 2026
pulisher
Feb 11, 2026

Nektar Therapeutics announces $300 million public offering By Investing.com - Investing.com South Africa

Feb 11, 2026
pulisher
Feb 11, 2026

Nektar Therapeutics Touts 52-Week ResPEG Data in Atopic Dermatitis, Eyes Phase 3 Launch in Q2 - MarketBeat

Feb 11, 2026
pulisher
Feb 10, 2026

BTIG Maintains Buy on Nektar Therapeutics (NKTR) Feb 2026 - Meyka

Feb 10, 2026
pulisher
Feb 10, 2026

Nektar Therapeutics (NKTR) Launches $300M Stock Offering - GuruFocus

Feb 10, 2026
pulisher
Feb 10, 2026

Nektar Therapeutics stock price target raised to $151 by BTIG - Investing.com UK

Feb 10, 2026
pulisher
Feb 10, 2026

Evommune, Nektar assets join list of recent successes in atopic derm - BioCentury

Feb 10, 2026
pulisher
Feb 10, 2026

Evommune, Nektar soar on atopic dermatitis phase II data - BioWorld MedTech

Feb 10, 2026
pulisher
Feb 10, 2026

Nektar Therapeutics announces $300 million public offering - Investing.com

Feb 10, 2026
pulisher
Feb 10, 2026

Maintenance results boost Nektar's case for IL-2 agonist in atopic dermatitis - FirstWord Pharma

Feb 10, 2026
pulisher
Feb 10, 2026

Nektar Therapeutics launches $300 mln equity offering after stock soars - TradingView

Feb 10, 2026
pulisher
Feb 10, 2026

Double Trouble For Dupixent? Biotechs Fly On Eczema Tests. - Investor's Business Daily

Feb 10, 2026
pulisher
Feb 10, 2026

Nektar Therapeutics (NKTR) Receives Boost with Analyst PT Raise | NKTR Stock News - GuruFocus

Feb 10, 2026
pulisher
Feb 10, 2026

Nektar Therapeutics (NKTR) Analyst Rating Update: Price Target R - GuruFocus

Feb 10, 2026
pulisher
Feb 10, 2026

BTIG Research Increases Nektar Therapeutics (NASDAQ:NKTR) Price Target to $151.00 - MarketBeat

Feb 10, 2026
pulisher
Feb 10, 2026

Nektar Therapeutics (NASDAQ:NKTR) Given New $165.00 Price Target at HC Wainwright - MarketBeat

Feb 10, 2026
pulisher
Feb 10, 2026

Nektar Therapeutics stock price target raised to $151 by BTIG By Investing.com - Investing.com India

Feb 10, 2026
pulisher
Feb 10, 2026

William Blair upgrades Nektar Therapeutics stock rating to Outperform By Investing.com - Investing.com Canada

Feb 10, 2026
pulisher
Feb 10, 2026

Biotech Stock Nektar Therapeutics (Nasdaq: NKTR) Makes Top Gainer List on News of REZOLVE-AD study - Investorideas.com

Feb 10, 2026

Nektar Therapeutics (NKTR) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$44.80
price up icon 1.24%
$26.75
price down icon 0.19%
$100.75
price up icon 1.93%
$105.76
price down icon 3.31%
$146.17
price down icon 1.52%
biotechnology ONC
$346.42
price down icon 1.38%
大文字化:     |  ボリューム (24 時間):